Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT00842361
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tagajo-shi, Japan
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2155
- Registration Number
- NCT00842192
- Locations
- 🇵🇰
Novo Nordisk Investigational Site, Karachi, Pakistan
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT00841087
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT00840086
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2092
- Registration Number
- NCT00839878
- Locations
- 🇧🇩
Novo Nordisk Investigational Site, Dhaka, Bangladesh
Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00837356
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 854
- Registration Number
- NCT00836030
- Locations
- 🇸🇬
Novo Nordisk Investigational Site, Singapore, Singapore
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 339
- Registration Number
- NCT00834262
- Locations
- 🇮🇱
Novo Nordisk Investigational Site, Kfar Saba, Israel
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00833716
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Knoxville, Tennessee, United States
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 75
- Registration Number
- NCT00832182
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
© Copyright 2024. All Rights Reserved by MedPath